-
CAS NUMBER
138402-11-6 -
FORMULATION
A - ORAL SOLID ORDINARY -
THERAPEUTIC CATEGORY
C-CARDIOVASCULAR SYSTEM -
STATUS
Commercial -
REGULATION
US DMF , CEP , EU DMF , Korea DMF , Canada DMF , Other
-
About the API
-
Molecular Formula: C25H28N6O
Molecular Weight: 428.529 g/mol
Systematic Name: 2-Butyl-3-{[2'-(2H-tetrazol-5-yl)-4-biphenylyl]methyl}-1,3-diazaspiro[4.4]non-1-en-4-one
Trade name(s): Avapro, Karvea
Physical Properties: white to off-white crystalline solid
-
-
API Expertise
-
The API expertise for producing Irbesartan is Synthetic Organic Chemistry.
For more information about Synthetic Organic Chemistry please click here
-
-
General
-
Irbesartan, structurally defined as a nonpeptide tetrazole derivative, is an angiotensin receptor blocker (ARB) used primarily for the treatment of hypertension. Irbesartan can be used alone, but is often prescribed with other medications, e.g. hydrochlorothiazide (marketed as Avalide) to treat hypertension.
Irbesartan may also slow the advancement of diabetic nephropathy, a disease of the blood vessels within the kidneys; for this reason, the drug is also used to treat kidney disorders in patients having both type-II diabetes and hypertension.
The U.S. FDA has recently approved (April 2012) the first generic versions of irbesartan (brand name Avapro). Presently, irbesartan is manufactured through an efficient large-scale multi-step synthetic organic process starting from simple, commercially available (petrochemical) precursors.
-
-
Mechanism of Action
-
Irbesartan and all ARB agents are primarily AT1-receptor antagonists'that is, the drug competes with angiotensin II for binding at the AT1-receptor subtype.
Irbesartan's inhibition of angiotensin II binding to the AT1 receptor leads to several effects including vasodilation, a reduction in secretion of vasopressin (a hormone involved in water retention), and reduction in production and secretion of aldosterone (a hormone involved in hypertension regulation). The resultant effect is a net decrease in blood pressure.
-
The information detailed herein, including that with regard to active pharmaceutical ingredients , their use in treatments and possible mechanism(s) of action, was all obtained from public sources.
For more information on our services and products – including product suitability, intended uses and current availability – please contact TAPI Customer Service. CAS Registry Number is a Registered Trademark of the American Chemical Society. This webpage and any reference to the above product is to be read within the meaning and terms of the Legal Notes
-
Visitors also viewed
-
111470-99-6
Amlodipine besylate
Innovators / Marketer
PfizerFORMULATION
A - ORAL SOLID ORDINARYB - ORAL SOLID LONG-ACTINGTHERAPEUTIC CATEGORY
C-CARDIOVASCULAR SYSTEMAvailable DMF/CEP
- US DMF
- CEP
- EU DMF
-
29122-68-7
Atenolol
Innovators / Marketer
Astra ZenecaFORMULATION
A - ORAL SOLID ORDINARYTHERAPEUTIC CATEGORY
C-CARDIOVASCULAR SYSTEMAvailable DMF/CEP
- US DMF
- CEP
- EU DMF
- Japan DMF
-
134523-03-08
Atorvastatin calcium
Innovators / Marketer
PfizerFORMULATION
A - ORAL SOLID ORDINARYTHERAPEUTIC CATEGORY
C-CARDIOVASCULAR SYSTEMAvailable DMF/CEP
- US DMF
- CEP
- EU DMF
- Korea DMF
- Canada DMF
- Brazil DMF
- Other
-
- Load More
-